- Hebrew SeniorLife: “Study: Stopping Certain Dementia Medications May Ease Treatment Burden Without Raising Nursing Home Risk Findings showed a lower risk of fall-related injuries” (Dec. 5, 2024)
- Birnbach Communications: “Birnbach Communications Issues Key Media, Business, Life Sciences and Tech Predictions for 2025” (Dec. 11, 2024)
- Hebrew SeniorLife: “Study: Stopping Certain Dementia Medications May Ease Treatment Burden Without Raising Nursing Home Risk Findings showed a lower risk of fall-related injuries” (Dec. 5, 2024)
- Hebrew SeniorLife: “Study Finds Abdominal Aortic Calcification Results Don’t Increase Fruit and Vegetable Intake Findings may improve cardiovascular risk management for older adults” (Oct. 31, 2024)
- Hebrew SeniorLife: “Hebrew SeniorLife Gets Grant to Expand Transitional Housing for Older Adults in Crisis Funding from the Administration for Community Living addresses the unique needs of at-risk older adults” (Oct. 29, 2024)
- Hebrew SeniorLife: “Hebrew SeniorLife’s EngAGE Event Features Governor Maura Healey and Host Andy Cohen Event raised funds to power Hebrew SeniorLife’s health care, communities, research, and teaching that transform the experience of aging” (Oct. 22, 2024)
- Hebrew SeniorLife: “Residents at NewBridge on the Charles and Orchard Cove Award 35 Educational Scholarships to Staff $1,155,000 distributed to employees since inception of scholarship committees” (Aug. 27, 2024)
- Hebrew SeniorLife: “Comprehensive Review Highlights Urgent Need for Frailty-Guided Clinical Care in Older Adults Frailty identified as a key predictor in older adult health care outcomes” (Aug. 21, 2024)
- Prota Therapeutics: “Prota Therapeutics Announces Publication in Allergy of Long-Term Peanut Allergy Study Confirming Clinical Remission as the Optimal Treatment Outcome” (Aug. 14, 2024)
- Akston Biosciences: “Purdue and Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development” (Aug. 13, 2024)
- Akston Biosciences: “Dechra Purchases Veterinary Insulin Programs from Akston Biosciences” (July 30, 2024)
- Hebrew SeniorLife: “Hydrogen-Rich Gas Inhalation Can Alleviate Exercise-Induced Fatigue New Study Published in the International Journal of Sports Medicine” (July 24, 2024)
- Birnbach Communications: “Birnbach Communications Expands Team, Deepens Expertise with KOGS Communication” (July 10, 2024)
- Immunic Therapeutic: “Immunic Appoints Jason Tardio as Chief Operating Officer and President” (July 9, 2024)
- Hebrew SeniorLife: “A New Training Program Facilitates Home-Based Transcranial Electrical Stimulation Home-based treatment can be easier and more accessible for older adults” (July 2, 2024)
- Hebrew SeniorLife: “Frailty Is a Major Determinant of Postoperative Outcomes in Older Adults, Regardless of Surgery: Study shows significant impact of frailty on mortality and home time loss” (June 27, 2024)
- Hebrew SeniorLife: “Study Investigates Vascular Dysfunction as Mechanism Underlying Link Between Heart and Bone Health in Older Adults Data collected from the Framingham Heart Study” (June 21, 2024)
- Akston BioSciences: “Dr. Linda Rhodes Joins Akston Biosciences’ Board of Directors” (June 17, 2024)
- Hebrew SeniorLife: “Hebrew SeniorLife’s Jack Satter House To Receive up to $20 Million HUD Grant To Support Energy Efficiency and Climate Resilience Efforts: Democratic Whip Katherine Clark, HUD New England Regional Administrator Juana B. Matias, and other officials attend grant announcement” (June 11, 2024)
- Hebrew SeniorLife: “Study Finds Link Between BMI Trajectories and Fracture Risk in Late Adulthood Findings highlight the importance of stable BMI throughout adulthood” (May 30, 2024)
- Hebrew SeniorLife: “29 Nurses at Hebrew SeniorLife Nominated for Annual Salute to Nurses Nurses praised for outstanding work, compassion by co-workers, patients, families” (May 7, 2024)
- Hebrew SeniorLife: “Class of Alzheimer’s Drug Presents Unique Challenge for Patients With Cardiovascular Disease, Says JAMA Article: Authors advocate for additional research to improve decision-making before initiating lecanemab” (March 28, 2024)
- Akston Biosciences: “Akston Biosciences’ AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility” (March 11, 2024)
- Hebrew SeniorLife: “Study Finds Higher Risk for Fracture From Falls in Men Than in Women Previous falls should be integrated in FRAX to increase predictive accuracy of future falls” (March 8, 2024)
- Akston Biosciences: “Akston Biosciences’ AKS-452 Vaccine Study Published in Nature, Showcasing Ambifect® Platform’s Versatility” (Feb. 26, 2024)
- Prota Therapeutics: “Prota Therapeutics US $21 Million Financing Led by SPRIM Global Investments” (Jan. 16, 2024)
- Birnbach Communications: “Birnbach Communications Issues Key Media, Business and Tech Predictions for 2024” (Jan. 9, 2024)
